What's new? Log in Free sign up

Qiagen (QGEN)

Company Profile

Company profile

Ticker

QGEN

Exchange

Website

CEO

Mr. Thierry Bernard

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment • BioNTech SE ...

Former names

QIAGEN NV

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

QGEN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$46.00

Low target

$42.00

High target

$48.00

Latest filings (excl ownership)

View all

QIAGEN delivers solid Q4 2024 growth ahead of outlook

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

QIAGEN delivers solid performance and exceeds outlook for Q2 2024

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

WELLINGTON MANAGEMENT GROUP LLP

WELLINGTON MANAGEMENT GROUP LLP

BlackRock, Inc.

BlackRock, Inc.

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Financial summary

Financial statements Chart QGEN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership, Q4 2024

QGEN institutional ownership history Ownership history

65.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	310	322	-3.7%
Opened positions	51	55	-7.3%
Closed positions	63	32	+96.9%
Increased positions	110	124	-11.3%
Reduced positions	104	105	-1.0%

13F shares	Current	Prev Q	Change
Total value	5.90 tn	6.34 tn	-6.9%
Total shares	142.79 mm	150.65 mm	-5.2%
Total puts	947.84 k	852.64 k	+11.2%
Total calls	1.55 mm	1.41 mm	+10.5%
Total put/call ratio	0.6	0.6	+0.6%

Largest owners	Shares	Value	Change
Massachusetts Financial Services	25.32 mm	$1.13 tn	+9.5%
Wellington Management	21.78 mm	$970.53 bn	+2.5%
Vanguard	8.88 mm	$397.94 bn	+0.9%
BlackRock	5.61 mm	$249.95 bn	+3.0%
Amundi	5.05 mm	$228.65 bn	-13.7%
Nuance Investments	4.15 mm	$184.58 bn	-7.7%
Norges Bank	4.07 mm	$181.53 bn	NEW
Earnest Partners	4.00 mm	$178.23 bn	+1.6%
BAC Bank of America	3.72 mm	$165.57 bn	-12.9%
MS Morgan Stanley	3.17 mm	$141.33 bn	-1.9%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	4.07 mm	+4.07 mm	NEW
Massachusetts Financial Services	25.32 mm	+2.20 mm	+9.5%
SEIC SEI Investments	11.50 k	-1.67 mm	-99.3%
Millennium Management	0.00	-1.32 mm	EXIT
Southpoint Capital Advisors	0.00	-1.30 mm	EXIT
Citadel Advisors	830.58 k	-1.28 mm	-60.7%
Caisse Des Depots Et Consignations	1.25 mm	+1.25 mm	NEW
JPM JPMorgan Chase & Co.	420.49 k	-1.18 mm	-73.8%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	3.00 mm	-1.15 mm	-27.8%
Amundi	5.05 mm	-799.26 k	-13.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Baird Downgrades Qiagen to Neutral, Lowers Price Target to $42

Baird analyst Catherine Schulte downgrades Qiagen (NYSE:QGEN) from Outperform to Neutral and lowers the price target from $52 to $42.

UBS Maintains Neutral on Qiagen, Lowers Price Target to $48

UBS analyst John Sourbeer maintains Qiagen (NYSE:QGEN) with a Neutral and lowers the price target from $50 to $48.

Qiagen Earnings Review: Q4 Summary

Qiagen Q4 Earnings Report: What Investors Need to Know

Press releases

From Benzinga Pro

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

New facility reflects QIAGEN's commitment to enhancing its bioinformatics data center infrastructure in the Australia, New Zealand, New Guinea and surrounding islands region New data center in Melbourne meets

QIAGEN delivers solid Q4 2024 growth ahead of outlook

Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the German Federal Patent Court (Bundespatentgericht) has ruled in its favor in a patent dispute against SD Biosensor, reaffirming the

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.